

HSE Drugs Group – February 2020 Minutes

Meeting 2020.02: Tuesday 11th February, 14.00

HSE PCERS, Exit 5 M50, Finglas

1. Draft Minutes for Consideration

The minutes of the January 2020 meeting were considered and approved.

2. Confidentiality forms

It had previously been agreed that all members (including public servants) would sign confidentiality forms (once off action).

3. Matters arising / Update on Medicines considered at previous meetings

CPU provided the members with an update in relation to items previously considered.

4. Updates / reports from TRCs

The National Cancer Control Programme Technology Review Committee's (NCCP TRC) recommendations to the HSE Drugs Group were considered for the applicable medicines on the agenda.

5. Declaration of Interests / Nil Interest

No potential conflicts arose.

6. Medicines for Consideration

i. 19020 Levodopa + Carbidopa Intestinal Gel (Duodopa®) for Parkinson's disease

The Drugs Group considered the expanded reimbursement of Levodopa and Carbidopa Intestinal Gel (LCIG) (Duodopa®) for the treatment of advanced Levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. The Group noted the updated clinical evidence alongside revised cost-effectiveness data. The Group reviewed expert input sought through the National Clinical Programme for Neurology regarding the advanced Parkinson's disease treatment pathway. The Group recognised Duodopa® provided a crucial option for patients with advanced Parkinson's disease who were unsuitable for other device aided therapies. The Group were minded to support a positive recommendation in favour of expanded reimbursement of Duodopa®.

ii. 20002 Venetoclax + Rituximab for Chronic Lymphocytic Leukaemia

The Drugs Group considered Venetoclax (Venclyxto®), in combination with Rituximab, for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy. The Group considered the clinical data, the resulting cost-effectiveness estimates and budget impact. The Group unanimously recommended in favour of reimbursement.

iii. 20001 Darvadstrocel for the treatment of complex perianal fistulas in Crohn's Disease

The Drugs Group unanimously did not support reimbursement of Darvadstrocel (Alofisel®) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. The Group were unable to support reimbursement in the absence of deliberations based on a more robust clinical evidence base and noted that the estimated completion date of ADMIRE-CD-

II is 2022. The Group recommended Darvadstrocel be referred to the Rare Diseases Technology Review Committee (RD TRC) when further clinical data became available.

7. AOB / Members Time

The date of the next meeting was confirmed as 10th March 2020.

Appendix 1: Members Present

Member	Title	Attendance
Prof. Áine Carroll	Chair, Medical Consultant	In attendance
Mr Shaun Flanagan	Primary Care Reimbursement Service (Assistant National Director)	In attendance
Ms Aoife Kirwan	Public Interest Member	Apologies received
Dr David Hanlon	National Clinical Advisor and Group Lead Primary Care (General Practitioner)	In attendance
Ms Patricia Heckmann For Ms Fiona Bonas	Chief Pharmacist, National Cancer Control Programme For Interim National Director of the National Cancer Control Programme	In attendance
Dr Philip Crowley	National Director for Quality Improvement (Medical Doctor)	Apologies received
Dr Valerie Walshe	Office of the Chief Financial Officer (Economist, PhD)	In attendance
Ms Joan Donegan	Office of Nursing & Midwifery Services (Director of Nursing)	In attendance
Dr Roy Browne	Mental Health Division (Consultant Psychiatrist)	In attendance
Position Vacant	Public Interest Member / Ethicist	Position Vacant
Mr Michael Power	Public Interest Member	Apologies received
Dr Kevin Kelleher	Health and Wellbeing Division (Assistant National Director – Public Health Physician)	Apologies received
Ms Angela Fitzgerald	Acute Services Division (Assistant National Director)	Apologies received
Prof Ellen Crushell	Consultant in Inherited Metabolic Disorders	In attendance
Dr Lisa Cogan	Consultant in Medicine for the Elderly, Medical Director, Royal Hospital Donnybrook	In attendance

In attendance (non-voting):

Professor Michael Barry (NCPE)

Ms Kate Mulvenna (KM), Head of Pharmacy Function/ CPU, PCRS

Secretariat:

Ms Maria Daly (MD), Chief II Pharmacist, CPU PCRS

Ms Lisa Kelly (LK), Chief II Pharmacist, CPU PCRS

Ms Fiona Mulligan (FM), Senior Pharmacist, CPU PCRS